Ajanta Pharma

Mumbai, India Founded: 1973 • Age: 53 yrs Listed Fortune India 500 · #488
Generic pharmaceutical products are manufactured across multiple therapeutic segments.
Request Access
Report Incorrect Data
Page last updated

About Ajanta Pharma

Ajanta Pharma is a publicly listed company based in Mumbai (India) founded in 1973 by Madhu Sudan Agrawal, Purshottam Agrawal, and Mannalal Agrawal. Generic pharmaceutical products are manufactured across multiple therapeutic segments. The company has 12,240 employees. Its website ajantapharma.com draws about 20 thousand monthly visits. Its Indian entity Ajanta Pharma Limited reported revenue of ₹5,625 Cr. Ajanta Pharma offers products and services including Branded Generics and Generics. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Ajanta Pharma was established in 1973 in Mumbai, India, within the pharmaceutical sector. Generic medicines are produced, with emphasis placed on quality and coverage of diverse molecules. Operations span therapeutic areas such as noncommunicable and infectious diseases, supported by a broad product portfolio. Focus is maintained on key segments to address various health needs.

Ajanta Pharma is ranked #488 on the Fortune India 500 (2025).

Recognitions & Rankings of Ajanta Pharma

Fortune India 500 2025 edition
Rank#488
Total income
₹4,768 Cr
Profit
₹920 Cr
Last year #476
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#169
Valuation
₹35,590 Cr
2023 #196 2022 #226 2021 #214
  • Headquarters Mumbai, India
  • Employees 12,240
  • Founders Madhu Sudan Agrawal, Purshottam Agrawal, Mannalal Agrawal
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website ajantapharma.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Ajanta Pharma Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹41,445 Cr

    AJANTPHARM · NSE

  • Share Price
    ₹3,282.10

    -1.04% today

  • Revenue
    ₹5,453 Cr

    FY 2025-26 · +17.3% YoY

  • EBITDA
    ₹1,395 Cr

    Margin 25.6%

  • Net Profit
    ₹1,129 Cr

    FY 2025-26 · +23.2% YoY

  • P/E (TTM)
    32.9x

    P/B 8.5x

  • ROE
    25.4%

    ROCE 31.8%

  • Debt / Equity
    0.04

    Interest cover 1.3x

  • Employee Count
    12,240

Products & Services of Ajanta Pharma

Ajanta Pharma offers a comprehensive portfolio of products and services, including Branded Generics and Generics.

Branded Generics
Pharmaceuticals

Branded generics are supplied for treatment in multiple therapeutic segments

Generics
Pharmaceuticals

Generics are distributed to various markets, including the USA and emerging regions

Apps and channels of Ajanta Pharma

its YouTube channel Ajanta Pharma has 3.55K subscribers and 30 videos.

Ajanta Pharma
YouTube 3.55K subscribers 30 videos Howto & Style
Open channel

Videos from Ajanta Pharma

The most watched videos on Ajanta Pharma's YouTube channel, Ajanta Pharma (3.55K subscribers). Click a video to play it here.

Factory Trek at Dahej Facility
2.7K views
Factory Trek at Guwahati Facility
1.9K views
Keeping Workplace Safe | COVID-19
804 views
50 Years of Ajanta Celebrations
715 views

More on Ajanta Pharma.

Board of directors of Ajanta Pharma Limited (Ajanta Pharma)

Ajanta Pharma Limited is the primary company behind Ajanta Pharma. The board of Ajanta Pharma Limited currently have 8 directors; the longest-serving is Madhusudan Bhagwandas Agrawal, appointed in 1979. 23 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Madhusudan Bhagwandas Agrawal
DIN 00073872
Whole-time director31 Dec 197946 yrs 10 moAjanta Pharma Limited
Mannalal Bhagwandas Agrawal
DIN 00073828
Director31 Dec 197946 yrs 10 moAjanta Pharma Limited
Yogesh Mannalal Agrawal
DIN 00073673
Managing Director01 Apr 200818 yrs 7 moAjanta Pharma Limited
Rajesh Mannalal Agrawal
DIN 00302467
Whole-time director30 Apr 201313 yrs 6 moAjanta Pharma Limited
David Paul Rasquinha
DIN 01172654
Director02 May 20242 yrs 6 moAjanta Pharma Limited
Medha Vinay Joshi
DIN 00328174
Director02 May 20242 yrs 6 moAjanta Pharma Limited
Simi Manohar Lal Thapar
DIN 10470498
Director02 May 20242 yrs 6 moAjanta Pharma Limited
Rajesh Shashikant Dalal
DIN 03504969
Director02 May 20242 yrs 6 moAjanta Pharma Limited

People of Ajanta Pharma

109 people are tracked at Ajanta Pharma (35 in leadership, 4 in board & advisors, 70 in team); the tracked headcount is 12,240.

NameRoleGroup
Madhu Sudan Agrawal
Co-FounderLeadership
Purshottam Agrawal
Co-FounderLeadership
Mannalal Agrawal
Co-Founder & OwnerLeadership
Rajesh Agrawal
Co-Managing DirectorLeadership
Yogesh Agrawal
Co-Managing DirectorLeadership
Vivekanand Singh
Associate General Manager – Learning And DevelopmentLeadership
Pramod S. Pandit
Executive Vice President - Commercial, Strategic Sourcing & External Supply OrganizationLeadership
Anil Pandey
General Manager Marketing Emerging Market Franco AfricaLeadership
Sathish Nayak
Sr General Manager Sales & MarketingLeadership
Tazeem Khan
National Business HeadLeadership
Girish M Modi
Marketing Head - Cardio & Diabeto TherapyLeadership
Sumeet Indulkar
Head Of Business DevelopmentLeadership
Jayakumar A V
President - QualityLeadership
Santosh Durge
General Manager - Human ResourceLeadership
Ca. Vishal Saraiya
Associate Vice PresidentLeadership
Dinesh Shukla .
Vice President Commercial. At Ajanta Pharma LtdLeadership
Rajesh Panchal
Deputy General Manager Human ResourcesLeadership
Sandeep Gadewar
Head- Analytical Sciences & Technology Transfer)Leadership
Gaurang Shah
Vp- Legal, Corporate Affairs & Company SecretaryLeadership
Pankaj Patil
Vice President Corporate QualityLeadership

89 more people are available in the full profile.

Premium access

Complete people profiles for Ajanta Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Ajanta Pharma

Ajanta Pharma is a publicly listed company on the NSE with ticker symbol AJANTPHARM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date29 May 2000
  • Listed onNSE: AJANTPHARM
  • Listed entityAjanta Pharma Limited
  • Exchange sectorHealth technology
  • ISININE031B01049
  • Share price₹3,299.00 (-0.88% on the day) · 2026-10-14
  • Market capitalisation₹41,753 Cr
  • Price to earnings36.3
  • EPS (diluted, trailing year)₹90.79
  • Dividend yield1.8%
  • Volume (last session)74,868

Financials of Ajanta Pharma

Exchange-reported figures of Ajanta Pharma Limited, the listed company behind Ajanta Pharma (NSE: AJANTPHARM).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹5,453 Cr
+17.3% YoY
EBITDA
₹1,395 Cr
+10.7% YoY
Profit After Tax
₹1,129 Cr
+23.2% YoY
Net Worth
₹4,527 Cr
+19.4% YoY
Total Assets
₹4,842 Cr
+23.5% YoY
Total Debt
₹260 Cr
+448.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue5,4534,6484,2093,7433,3412,8902,588
Revenue growth+17.3%+10.4%+12.5%+12.0%+15.6%+11.7%-
EBITDA1,3951,2601,172783929999679
EBITDA margin+25.6%+27.1%+27.9%+20.9%+27.8%+34.6%+26.3%
Profit before tax1,3781,1891,114745909900664
Net profit1,129916808594713651471
Net profit margin+20.7%+19.7%+19.2%+15.9%+21.4%+22.5%+18.2%
EPS (₹)84.2473.4364.6046.5483.0175.2053.33
Balance sheet
Total assets4,8423,9213,6463,4513,3133,0502,694
Net worth4,5273,7903,5673,3883,2642,9962,599
Total debt26047.4235.2835.6325.0331.3674.96
Cash & bank105176131331212210205
Net working capital1,9811,4211,5171,1941,5021,2151,031
Cash flow
Cash from operations5291,157785792562576457
Cash from investing(429)(377)65.39(560)(74.10)(282)(224)
Cash from financing(168)(733)(1,051)(108)(460)(318)(129)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,7941,6261,4221,3751,3541,3031,1701,146
Revenue growth (YoY)+32.5%+24.8%+21.5%+20.0%+14.1%+13.8%--
Other income37.3970.9061.4324.9759.3426.3318.1130.44
EBITDA548424333382328351297321
EBITDA margin+30.5%+26.1%+23.5%+27.8%+24.2%+27.0%+25.4%+28.0%
Depreciation47.5644.5045.3743.5142.9741.2939.7835.97
Interest2.243.182.365.103.395.266.077.91
Profit before tax535447347359341331269307
Tax14711380.4184.8380.6275.7944.1574.51
Net profit388334267274260255225233
EPS (₹)31.0726.7221.3421.9120.8220.4318.0018.59
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,8464,3223,9713,4113,1412,7192,196
Revenue growth+12.1%+8.8%+16.4%+8.6%+15.5%+23.8%-
EBITDA1,1981,2051,119699891917529
EBITDA margin+24.7%+27.9%+28.2%+20.5%+28.4%+33.7%+24.1%
Profit before tax1,2311,1801,097700901902613
Net profit942906796546720673444
Net profit margin+19.4%+21.0%+20.1%+16.0%+22.9%+24.8%+20.2%
EPS (₹)75.5373.1563.8944.2283.8577.7050.30
Balance sheet
Total assets4,3133,7403,4873,3073,2132,9332,505
Net worth4,2243,6253,4143,2463,1692,8852,461
Total debt34.6931.1730.5232.9020.4925.9123.49
Cash & bank90.5549.7263.0627014515287.85
Net working capital1,6731,4331,4901,1411,4701,191885
Cash flow
Cash from operations8041,054735736542467301
Cash from investing(400)(350)105(501)(66.04)(163)(116)
Cash from financing(360)(716)(1,048)(105)(457)(269)(134)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,7251,4891,2111,2071,2201,2091,0141,102
Revenue growth (YoY)+41.4%+23.2%+19.4%+9.5%+8.1%+12.2%--
Other income52.6270.8262.9825.7675.0340.6317.9333.23
Total expenses1,2081,092972866931879764766
EBITDA517397238341290329250336
EBITDA margin+30.0%+26.6%+19.7%+28.3%+23.7%+27.3%+24.6%+30.5%
Depreciation46.3043.3144.1642.3841.9240.3138.7634.93
Interest0.790.76(0.74)1.870.730.730.672.48
Profit before tax523423258322322329228332
Tax14310860.3377.4272.4474.0234.7279.70

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 05 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,7941,6261,4221,3751,3541,3031,1701,146
Revenue growth (YoY)+32.5%+24.8%+21.5%+20.0%+14.1%+13.8%--
Other income37.3970.9061.4324.9759.3426.3318.1130.44
EBITDA548424333382328351297321
EBITDA margin+30.5%+26.1%+23.5%+27.8%+24.2%+27.0%+25.4%+28.0%
Depreciation47.5644.5045.3743.5142.9741.2939.7835.97
Interest2.243.182.365.103.395.266.077.91
Profit before tax535447347359341331269307
Tax14711380.4184.8380.6275.7944.1574.51
Net profit388334267274260255225233
EPS (₹)31.0726.7221.3421.9120.8220.4318.0018.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue5,4534,6484,2093,7433,3412,8902,588
Revenue growth+17.3%+10.4%+12.5%+12.0%+15.6%+11.7%-
Other income17294.5084.6098.6411625.9892.19
Total expenses4,0583,3893,0372,9592,4121,8911,908
Employee cost1,2911,090900785646548486
EBITDA1,3951,2601,172783929999679
EBITDA margin+25.6%+27.1%+27.9%+20.9%+27.8%+34.6%+26.3%
Depreciation17314413513112511695.72
Interest16.1120.737.215.8410.208.2711.91
Profit before tax1,3781,1891,114745909900664
Tax322269298157197246196
Net profit1,129916808594713651471
Net profit margin+20.7%+19.7%+19.2%+15.9%+21.4%+22.5%+18.2%
EPS (₹)84.2473.4364.6046.5483.0175.2053.33
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.0725.0725.2725.2717.1717.3917.54
Reserves & surplus4,5023,7653,5423,3633,2472,9782,581
Shareholders' funds (net worth)4,5273,7903,5673,3883,2642,9962,599
Minority interest0.000.000.000.000.000.000.00
Secured loans2122.591.491.431.911.6945.68
Unsecured loans48.1844.8333.7934.2023.1229.6729.28
Total debt26047.4235.2835.6325.0331.3674.96
Total liabilities4,8423,9213,6463,4513,3133,0502,694
Assets
Gross block3,0462,8012,3892,2832,2182,1411,975
Net block1,8671,7621,4791,4961,5121,5411,472
Capital work in progress258176256209153108132
Investments58846434953514717679.42
Inventories939904828816791766496
Sundry debtors1,8541,1831,2471,0571,020738775
Cash & bank balances105176131331212210205
Loans & advances27814119512012013798.34
Total current assets3,1762,4042,4012,3242,1431,8521,575
Total current liabilities1,1959838841,130641637544
Net working capital1,9811,4211,5171,1941,5021,2151,031
Total assets4,8423,9213,6463,4513,3133,0502,694
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash17512933020617820295.16
Net cash from operating activities5291,157785792562576457
Net cash from investing activities(429)(377)65.39(560)(74.10)(282)(224)
Net cash from financing activities(168)(733)(1,051)(108)(460)(318)(129)
Net change in cash(67.65)47.30(201)12427.90(24.36)104
Closing cash105176131331212210205
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.3%+10.4%+12.5%+12.0%+15.6%+11.7%-
EBITDA growth+10.7%+7.5%+49.6%-15.7%-6.9%+47.0%-
PBT growth+15.9%+6.8%+49.5%-18.1%+1.0%+35.6%+29.1%
Net income growth+23.2%+13.4%+36.0%-16.7%+9.5%+38.4%-
Revenue CAGR (3Y)+13.4%+11.6%+13.4%+13.1%+17.6%+10.8%+9.3%
EBITDA CAGR (3Y)+21.2%+10.7%+5.5%+4.9%+17.9%+14.9%-0.4%
Profitability & leverage
Net income margin+19.4%+19.8%+19.4%+15.7%+21.3%+22.6%+18.1%
Return on capital employed+31.8%+32.0%+31.6%+22.2%+28.9%+31.6%+27.1%
Return on net worth+25.4%+25.0%+23.5%+17.7%+22.8%+23.4%+19.3%
Debt / equity0.040.010.010.010.010.020.02
Long-term debt / equity0.010.010.010.010.010.010.00
Interest cover1.321.860.700.901.270.942.04
Efficiency & per share
Fixed asset turnover1.871.791.801.661.531.401.45
Inventory turnover5.925.375.124.664.294.585.56
Debtors turnover3.593.833.653.603.803.824.19
EPS (₹)84.2473.4364.6046.5483.0175.2053.33
Dividend per share (₹)28.0028.0051.007.009.509.5013.00
Book value per share (₹)361.16302.38282.34268.14380.24344.52296.34
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,7251,4891,2111,2071,2201,2091,0141,102
Revenue growth (YoY)+41.4%+23.2%+19.4%+9.5%+8.1%+12.2%--
Other income52.6270.8262.9825.7675.0340.6317.9333.23
Total expenses1,2081,092972866931879764766
EBITDA517397238341290329250336
EBITDA margin+30.0%+26.6%+19.7%+28.3%+23.7%+27.3%+24.6%+30.5%
Depreciation46.3043.3144.1642.3841.9240.3138.7634.93
Interest0.790.76(0.74)1.870.730.730.672.48
Profit before tax523423258322322329228332
Tax14310860.3377.4272.4474.0234.7279.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,8464,3223,9713,4113,1412,7192,196
Revenue growth+12.1%+8.8%+16.4%+8.6%+15.5%+23.8%-
Other income204120116133140104184
Total expenses3,6483,1172,8522,7122,2501,8021,668
Employee cost1,1941,011834720586498438
EBITDA1,1981,2051,119699891917529
EBITDA margin+24.7%+27.9%+28.2%+20.5%+28.4%+33.7%+24.1%
Depreciation16914013212712111191.29
Interest2.594.606.805.239.126.909.10
Profit before tax1,2311,1801,097700901902613
Tax284263290141181226172
Net profit942906796546720673444
Net profit margin+19.4%+21.0%+20.1%+16.0%+22.9%+24.8%+20.2%
EPS (₹)75.5373.1563.8944.2283.8577.7050.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.0725.0725.2725.2717.1717.3917.54
Reserves & surplus4,1983,6003,3883,2213,1522,8682,444
Shareholders' funds (net worth)4,2243,6253,4143,2463,1692,8852,461
Secured loans0.000.000.000.000.000.000.00
Unsecured loans34.6931.1730.5232.9020.4925.9123.49
Total debt34.6931.1730.5232.9020.4925.9123.49
Total liabilities4,3133,7403,4873,3073,2132,9332,505
Assets
Gross block2,9962,7602,3552,2462,1632,0871,927
Net block1,8451,7421,4651,4841,4921,5191,449
Capital work in progress258176256209153108131
Investments60648236755316515785.77
Inventories845739678684635634436
Sundry debtors1,3661,2261,2089781,044782734
Cash & bank balances90.5549.7263.0627014515287.85
Loans & advances25812316311011112989.66
Total current assets2,5592,1372,1122,0411,9351,6971,348
Total current liabilities886704622900466506463
Net working capital1,6731,4331,4901,1411,4701,191885
Total assets4,3133,7403,4873,3073,2132,9332,505
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash48.6061.7826914012084.9530.52
Net cash from operating activities8041,054735736542467301
Net cash from investing activities(400)(350)105(501)(66.04)(163)(116)
Net cash from financing activities(360)(716)(1,048)(105)(457)(269)(134)
Net change in cash44.65(11.51)(207)13019.0035.4150.97
Closing cash90.5549.7263.0627014515287.85
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.1%+8.8%+16.4%+8.6%+15.5%+23.8%-
EBITDA growth-0.6%+7.6%+60.1%-21.5%-2.8%+73.4%-
PBT growth+4.3%+7.6%+56.7%-22.3%-0.2%+47.2%+19.4%
Net income growth+3.9%+13.8%+45.9%-24.2%+7.1%+51.5%-
Revenue CAGR (3Y)+12.4%+11.2%+13.5%+15.8%+21.0%+14.2%+6.8%
EBITDA CAGR (3Y)+19.7%+10.6%+6.9%+9.8%+22.8%+18.8%-5.9%
Profitability & leverage
Net income margin+19.5%+21.2%+20.3%+16.4%+22.9%+24.9%+20.1%
Return on capital employed+30.6%+32.8%+32.5%+21.6%+29.6%+33.4%+26.7%
Return on net worth+24.1%+26.1%+24.2%+17.4%+23.8%+25.3%+19.2%
Debt / equity0.010.010.010.010.010.010.01
Long-term debt / equity0.010.010.010.010.010.010.00
Interest cover0.250.430.690.911.180.862.08
Efficiency & per share
Fixed asset turnover1.681.691.731.551.481.351.26
Inventory turnover6.126.105.835.174.955.085.17
Debtors turnover3.743.553.633.383.443.593.79
EPS (₹)75.5373.1563.8944.2283.8577.7050.30
Dividend per share (₹)28.0028.0051.007.009.509.5013.00
Book value per share (₹)336.94289.21270.17256.94369.15331.80280.65

Web traffic of Ajanta Pharma

The website of Ajanta Pharma (ajantapharma.com) receives about 20.1K visits a month and ranks #1,412,069 among all websites worldwide, #1,830 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    20.1K

    ▲ 40.5% vs previous month

  • Unique visitors
    7.2K

    per month

  • Global rank
    #1,412,069

    among all websites

  • Category rank
    #1,830

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Ajanta Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Albert David India
albertdavidindia.com
100%
3.2K#6,337,167View details
Mangalam Drugs
mangalamdrugs.com
89%
9.9K#1,747,627View details
Alembic Pharmaceuticals
alembicpharmaceuticals.com
87%
23K#2,083,600View details
Natco Pharma
natcopharma.co.in
87%
19.8K#1,133,324View details
Lupin
lupin.com
87%
216.4K#208,025View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Ajanta Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Ajanta Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ajanta Pharma

AJANTPHARM: Q2 CONS NET PROFIT 3.9B RUPEES VS 2.6B (YOY)
Exchange Update • 6 days ago
AJANTPHARM: Q2 REVENUE 18B RUPEES VS 13.5B (YOY)
Exchange Update • 6 days ago
AJANTPHARM: Q2 EBITDA 5.5B RUPEES VS 3.3B (YOY); Q2 EBITDA MARGIN 30.52% VS 24.22% (YOY)
Exchange Update • 6 days ago
AJANTPHARM: Rs. 16.84 Crores NSE Block Trade; for ~ 50,812 Shares, at Rs. 3313.90
Exchange Update • 13 days ago
Ajanta Pharma Ltd slips for fifth straight session | Capital Market News - Business Standard
Business Standard • 2 months ago
Ajanta Pharma shares gain 2.04% in today's session
Moneycontrol • 2 months ago
Ajanta Pharma Shares Rise 2.17%
Moneycontrol • 2 months ago
Ajanta Pharma shares gain 2.16% to Rs 3,617.40; stock among top gainers on Nifty Midcap 150
Moneycontrol • 2 months ago
Ajanta Pharma shares decline 2.05% at Rs 3,452.70 on Wednesday morning
Moneycontrol • 3 months ago
Ajanta Pharma Ltd soars 0.37%, rises for fifth straight session | Capital Market News - Business Standard
Business Standard • 3 months ago
Premium access

Complete news archive for Ajanta Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ajanta Pharma

Ajanta Pharma was founded in 1973.

Ajanta Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Ajanta Pharma has 12,240 employees.

The primary company behind Ajanta Pharma, Ajanta Pharma Limited, reported revenue of ₹5,625 Cr for FY 2026, up 17% year on year.

Ajanta Pharma was established in 1973 in Mumbai, India, within the pharmaceutical sector. Generic medicines are produced, with emphasis placed on quality and coverage of diverse molecules. Operations span therapeutic areas such as noncommunicable and infectious diseases, supported by a broad product portfolio. Focus is maintained on key segments to address various health needs.

Ajanta Pharma offers Branded Generics and Generics.

Yes, Ajanta Pharma is publicly traded on NSE under the ticker symbol AJANTPHARM.

Ajanta Pharma operates through Ajanta Pharma Limited.

The legal entities of Ajanta Pharma currently have 10 directors, including Arvind Kanhaiyalal Agrawal, Madhusudan Bhagwandas Agrawal, Rajesh Mannalal Agrawal and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available